ClinicalTrials.gg

Program

mavorixafor

Also written as “Mavorixafor”, “X4P-001” and “AMD11070”.

Its studies are mostly in Neutropenia · Carcinoma, Renal Cell · Hepatic Insufficiency · Waldenstrom Macroglobulinemia · Triple Negative Breast Neoplasms, led by 3 companies.

Furthest: phase 3, since Jun 19, 201914 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
X4 Pharmaceuticals122 open or runningphase 3since Jun 19, 2019Jan 20, 2016Sep 2027phase 3 · NCT06056297
Abbisko Cayman10 open or runningphase 2since Sep 25, 2021Sep 25, 2021none ahead
Sanofi10 open or runningphase 1since Aug 3, 2006Aug 3, 2006none ahead

Also a collaborator on its studies: covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2006First study: phase 1 study in HIV InfectionsNew to SanofiSanofi · NCT00361101 · 10 enrolled · United States, United Kingdom
  2. Jan 20, 2016X4 Pharmaceuticals's first study: phase 2 study in Carcinoma, Renal CellNew to X4 PharmaceuticalsX4 Pharmaceuticals · NCT02667886 · 74 enrolled · United States, Korea, Republic of
  3. Feb 4, 2016Phase 1 study in HealthyX4 Pharmaceuticals · NCT02680782 · 15 enrolled · United States
  4. Jul 1, 2016Phase 1 study in MelanomaX4 Pharmaceuticals · NCT02823405 · 16 enrolled · United States
  5. Sep 30, 2016Phase 2 study in Carcinoma, Renal CellX4 Pharmaceuticals · NCT02923531 · 9 enrolled · United States
  6. Dec 20, 2016Phase 2 study in WHIM syndromeX4 Pharmaceuticals · NCT03005327 · 8 enrolled · United States, Australia
  7. Jun 19, 2019Phase 3 study in WHIM syndromeX4 Pharmaceuticals · NCT03995108 · 31 enrolled · United States, Australia, Austria and more
  8. Nov 4, 2019Phase 2 study in NeutropeniaX4 Pharmaceuticals · NCT04154488 · 32 enrolled · United States
  9. Feb 12, 2020Phase 1 study in Waldenstrom MacroglobulinemiaX4 Pharmaceuticals · NCT04274738 · 16 enrolled · United States, Greece
  10. Sep 25, 2021Abbisko Cayman's first study: phase 2 study in Triple Negative Breast NeoplasmsNew to Abbisko CaymanAbbisko Cayman · NCT05103917 · 24 enrolled · China
  11. Sep 20, 2023Phase 3 study in NeutropeniaX4 Pharmaceuticals · NCT06056297 · 176 planned · United States, Argentina, Australia and more
  12. Feb 27, 20252 phase 1 studiesX4 Pharmaceuticals · NCT06914869, NCT06858696
  13. Oct 20, 2026Phase 2 study in Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersX4 Pharmaceuticals · NCT07902830 · 40 planned

Ahead

  1. Sep 2027Primary completion: phase 3 study in NeutropeniaX4 Pharmaceuticals · NCT06056297
  2. Jan 30, 2029Primary completion: phase 2 study in Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersX4 Pharmaceuticals · NCT07902830

TargetBeta

CXCR4 →read by rule
“An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), ”NCIt, by rule
“C-X-C chemokine receptor type 4 antagonist”ChEMBL 37, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07902830Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders2Not yet recruitingX4 PharmaceuticalsJan 30, 202940
NCT06914869Healthy Participants · United States1CompletedX4 PharmaceuticalsMay 19, 202538
NCT06858696Hepatic Insufficiency · United States1CompletedX4 PharmaceuticalsJan 12, 202639
NCT06056297Neutropenia · United States, Argentina, Australia and more3RecruitingX4 PharmaceuticalsSep 2027176
NCT05103917Triple Negative Breast Neoplasms · China2UNKNOWNAbbisko CaymanNov 24, 202224
NCT04274738Waldenstrom Macroglobulinemia · United States, Greece1CompletedX4 PharmaceuticalsOct 31, 202216
NCT04154488Neutropenia · United States2CompletedX4 PharmaceuticalsAug 27, 202432
NCT03995108WHIM syndrome · United States, Australia, Austria and more3CompletedX4 PharmaceuticalsDec 23, 202531
NCT03005327WHIM syndrome · United States, Australia2CompletedX4 PharmaceuticalsJun 16, 20228
NCT02923531Carcinoma, Renal Cell · United States2TerminatedX4 PharmaceuticalsAug 8, 20189
NCT02823405Melanoma · United States1CompletedX4 PharmaceuticalsMar 15, 201816
NCT02680782Healthy · United States1TerminatedX4 PharmaceuticalsFeb 28, 201615
NCT02667886Carcinoma, Renal Cell · United States, Korea, Republic of2CompletedX4 PharmaceuticalsApr 14, 202274
NCT00361101HIV Infections · United States, United Kingdom1CompletedSanofiAug 200610

How it is read

Names in the registry

  • “Mavorixafor”, 7 entries
  • “X4P-001”, 6 entries
  • “AMD11070”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.